dc.contributor.author | Catovsky, D | |
dc.date.accessioned | 2018-07-13T10:16:18Z | |
dc.date.issued | 2011-02 | |
dc.identifier | http://publications.icr.ac.uk/10431/ | |
dc.identifier.citation | BLOOD, 2011, 117 (5), pp. 1516 - 1521 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2055 | |
dc.description.abstract | We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first-or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = 111). Median EFS was 24.4 months (range, 16.7-32 months) in the observation group and 51.2 months (39.8-62.5 months) in the autografting group; the 5-year EFS was 24% and 42%, respectively (P < .001). Accordingly, the 5-year relapse incidence was 76% versus 54% (P < .001). Median time to relapse requiring therapy or death was 40 months (25-56 months) in the observation arm and 65 months (59-71 months) after autografting (P = .002). Cox modeling confirmed that autografting significantly improved EFS (hazard ratio 0.44, 95% confidence interval 0.30-0.65; P < .001). At 5 years, the probability of OS was 85.5% and 84.3% for autografting and observation, respectively (P = .77). In chronic lymphocytic leukemia, consolidating autografting reduces the risk of progression by more than 50% but has no effect on overall survival. (Blood. 2011; 117(5):1516-1521) | |
dc.format.extent | 1516 - 1521 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER SOC HEMATOLOGY | |
dc.subject | BONE-MARROW-TRANSPLANTATION; RESIDUAL DISEASE; MATCHED ANALYSIS; FLUDARABINE; CYCLOPHOSPHAMIDE; RITUXIMAB; GENE; MOBILIZATION; ALEMTUZUMAB; DIAGNOSIS | |
dc.title | Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation | |
dc.type | Journal Article | |
rioxxterms.licenseref.startdate | 2011-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | BLOOD | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.volume | 117 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Catovsky, Daniel | en |